How much does gilteritinib cost in the country?

Gilteritinib is an oral, potent, selective FLT3 inhibitor with single-agent activity against relapsed or refractory FLT3mutatedAML. Giritinib is used to treat a certain type of acute myeloid leukemia(AML) that gets worse or comes back after treatment with other chemotherapy drugs.

Giritinib was approved by the China Food and Drug Administration for marketing on January 1, 2021, and March 31, 2021. However, it has not been included in medical insurance and cannot be reimbursed. The current domestic retail price is 40mg*21tablets*2board258,000yuan. Patients can also choose generic drugs if they consider the economy. The current retail price of pharmaceutical manufacturers40mg90tablets4000 is about . Patients can choose the drug version according to their own economic situation. The most common adverse reactions of giritinib(≥20%)are elevated transaminase, myalgia, arthralgia, fatigue and discomfort, fever, mucositis, edema, rash, non-infectious diarrhea, dyspnea, nausea, cough, constipation, eye disease, headache, dizziness, hypotension, vomiting and renal damage.

In a Phase 3 trial, adults with relapsed or refractory FLT3-mutated were randomly assigned in a 2:1 ratio. n>AMLreceives Gtinib (dose is 120mg/day) or salvage chemotherapy. The two primary endpoints were overall survival and the percentage of patients with complete response and complete or partial hematologic recovery. Secondary endpoints included event-free survival and the percentage of patients with complete response. Results:Among 371 eligible patients, 247124 patients were randomly assigned to the gyrosinib group, and 124 patients were assigned to the salvage chemotherapy group. The median overall survival of the gesatinib group was significantly longer than that of the chemotherapy group (9.3 months vs. 5.6 months; the hazard ratio of death was 0.64; 95% an>Confidence interval[CI], 0.49 to 0.83; P<0.001). The median event-free survival was 2.8 months in the girutinib group and 0.7 months in the chemotherapy group. (The hazard ratio for treatment failure or death was pan>0.79; 95% confidence interval is 0.58 to 1.09). The percentage of patients with complete response and complete or partial hematological recovery was 34.0% in the gesatinib group and 15.3% in the chemotherapy group (risk difference, 18.6percentage points;95%The confidence interval is9.8to27.4) span>; the percentages of complete responses were 21.1% and 10.5% (Risk difference, 10.6 span>percentage points;95%confidence interval is 2.8to18.4). In analyzes adjusting for duration of treatment, the incidence of grade 3 or higher adverse events and serious adverse events was lower in the gesatinib group than in the chemotherapy group; the most common grade 3 or higher adverse events in the gesatinib group They were febrile neutropenia (45.9%), anemia (40.7%) and thrombocytopenia (22.8%). Conclusion:In patients with relapsed or refractory acute myeloid leukemia, compared with salvage chemotherapy, girutinib can significantly prolong survival and increase the percentage of patients with relapsed FLT3 mutated acute myeloid leukemia. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0